Compare G & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | G | GRFS |
|---|---|---|
| Founded | 1997 | 1940 |
| Country | Bermuda | Spain |
| Employees | 140000 | 25247 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.0B |
| IPO Year | 2007 | N/A |
| Metric | G | GRFS |
|---|---|---|
| Price | $29.10 | $7.16 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $49.50 | $10.15 |
| AVG Volume (30 Days) | ★ 2.6M | 657.9K |
| Earning Date | 05-07-2026 | 07-28-2022 |
| Dividend Yield | ★ 2.21% | 1.80% |
| EPS Growth | ★ 9.82 | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $2,279,438,000.00 | N/A |
| Revenue This Year | $9.20 | $4.49 |
| Revenue Next Year | $7.27 | $6.42 |
| P/E Ratio | $33.86 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.85 | $6.96 |
| 52 Week High | $48.64 | $11.14 |
| Indicator | G | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 43.64 | 38.73 |
| Support Level | $28.78 | N/A |
| Resistance Level | $35.09 | $7.73 |
| Average True Range (ATR) | 1.12 | 0.16 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 39.75 | 25.97 |
Genpact Ltd is an agentic, technology-solutions company offering digital transformation, data-driven operations, and technology-enabled services across multiple industries. Its core business services include decision support services; technology services like application lifecycle management, platform customization, and support, etc; and digital operations optimizing business processes. Genpact also offers data engineering, data management, and domain-based AI and generative AI solutions; develops new technology solutions for clients; and offers agentic solutions and technology consulting services. Its reportable segments are: High Tech and Manufacturing, which generate maximum revenue, Financial Services, and Consumer and Healthcare. Geographically, it derives maximum revenue from India.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.